6533b862fe1ef96bd12c76dc

RESEARCH PRODUCT

Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report

Célia VauryAntonin SchmittPascal GuerardBruno CoudertPauline MacaireFrançoise Goirand

subject

Oncologymedicine.medical_specialtyPyridinesBreast NeoplasmsPiperazines03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)EverolimusAgedEverolimusbusiness.industrymedicine.diseaseMetastatic breast cancerAndrostadienesOncology030220 oncology & carcinogenesisDisease ProgressionPleural fluidFemalebusiness030215 immunologymedicine.drug

description

Background We report here a case where no everolimus pleural diffusion was evidenced at the same time of pleural progression of a metastatic breast cancer treated with everolimus and exemestane. Case description A 69-year-old woman was diagnosed in October 2006 with stage III invasive ductal breast adenocarcinoma. After nine months of everolimus and exemestane treatment, she presented with a pleural progression. Everolimus concentration was measured in blood and in pleural fluid. Residual blood concentration was at 9.1 ng/mL, while no everolimus was observed in the pleural fluid. Management and outcome Due to inefficacy of everolimus in this patient, she was switched to palbociclib and fulvestrant. Conclusion Everolimus seems to have a poor diffusion in the pleural fluid.

yearjournalcountryeditionlanguage
2020-06-05Journal of Oncology Pharmacy Practice
https://doi.org/10.1177/1078155220927771